Financial Performance
Pathology Revenue Cycle Consulting
Volume does not create sustainable growth when reimbursement performance is unclear. Pathology revenue cycle consulting gives laboratory leaders better visibility into collections, denials, aging receivables, coding concerns, payer behavior, and billing-partner performance so financial decisions are based on evidence.
Who this service helps
- Independent laboratories seeking better billing visibility
- Pathology practices concerned about collections or denial trends
- Executives evaluating a billing partner or revenue-cycle model
- Growth-stage laboratories aligning commercial activity with realized revenue
What the work can accomplish
- A clear view of where earned revenue is delayed, denied, or lost
- Meaningful performance measures for internal teams and billing partners
- Prioritized actions across coding, documentation, denials, and follow-up
- Better alignment between sales growth, payer mix, operational cost, and cash
How we approach it
- We clarify the financial and operating questions leadership needs the revenue-cycle data to answer.
- We review available collection, denial, aging, coding, payer, and billing-partner performance indicators.
- We identify the gaps that prevent leaders from separating operational, documentation, payer, and vendor issues.
- We establish a practical improvement agenda and management reporting cadence.
Practical consulting deliverables
- Revenue-cycle visibility and reporting framework
- Collection, denial, and aging performance assessment
- Billing-partner evaluation criteria
- Prioritized financial performance roadmap
Engagement scope
Revenue-cycle work can begin as an executive visibility assessment or focus on a defined issue such as denial growth, aging receivables, coding concerns, or billing-partner accountability.
Experienced pathology leadership
David “DJ” Dalton, PhD, MBA brings more than 20 years of pathology industry experience spanning Labcorp, Paige AI, Lumea/Modella AI, digital pathology, laboratory operations, product strategy, commercialization, and executive leadership.
Last reviewed September 2026. About David Dalton
Frequently asked questions
Which pathology revenue-cycle metrics should leadership monitor?
Leadership should understand net collection performance, denial rate and root causes, days in accounts receivable, aging distribution, write-offs, payer mix, coding trends, and performance by service or client where reliable data is available.
How do we know whether the problem is our billing partner?
A billing partner should be evaluated using transparent definitions, trend data, denial ownership, follow-up performance, reporting quality, and the laboratory's own documentation and operational responsibilities. Poor results may have multiple causes.
Can revenue-cycle improvement support laboratory growth?
Yes. Growth should be evaluated on realized contribution, not specimen volume alone. Better revenue visibility helps determine which services, clients, payer mixes, and commercial programs create sustainable value.